研究人员提出的递归语言模型（Recursive Language Models, RLMs）通过引入Python交互环境，让模型学会写代码去分块读取、检索并递归调用自身处理信息，成功在千万级Token的超长文本任务中实现了性能与成本的双重突破。

2025年的最后一天， MIT CSAIL提交了一份具有分量的工作。当整个业界都在疯狂卷模型上下文窗口（Context ...

Author Shawn Peters blends clarity and rigor to make data structures and algorithms accessible to all learners. COLORADO, CO, UNITED STATES, January 2, 2026 /EINPresswire.com/ — Vibrant Publishers ...

其核心思想是借鉴计算机科学中的“外存算法” (Out-of-core algorithms)，不要把长 Prompt 直接喂给神经网络，而是把它放在一个外部的 Python REPL 环境里。 Prompt 被加载为环境中的变量context 。模型不再像以前那样生吞整个字符串，而是通过编写代码（如len (context) , context.split , re.search ）来按需读取数据 ...

The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental ...

Abstract: Complicated deformation problems are frequently encountered in medical image registration tasks. Although various advanced registration models have been proposed, accurate and efficient ...

Abstract: We present two computing projects, peridynamics simulation and numerical integration on implicit domains, for which we realized high performance implementations using Python with appropriate ...

modelx is a numerical computing tool that enables you to use Python like a spreadsheet by quickly defining cached functions. modelx is best suited for implementing mathematical models expressed in a ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

This project is intended for enumerating PCI devices in the system without any interferences from OS. Hopefully the following commands can help you setup and build ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...